These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35429171)

  • 1. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.
    Ahn JC; Lauzon M; Luu M; Noureddin M; Ayoub W; Kuo A; Sundaram V; Kosari K; Nissen N; Gong J; Hendifar A; Roberts LR; Abou-Alfa GK; Singal AG; Yang JD
    Hepatology; 2022 Dec; 76(6):1649-1659. PubMed ID: 35429171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.
    Rich NE; Hester C; Odewole M; Murphy CC; Parikh ND; Marrero JA; Yopp AC; Singal AG
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):551-559.e1. PubMed ID: 29859983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
    Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
    Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative.
    Lee RM; Gamboa AC; Turgeon MK; Yopp A; Ryon EL; Kronenfeld JP; Goel N; Wang A; Lee AY; Luu S; Hsu C; Silberfein E; Maithel SK; Russell MC
    Surg Oncol; 2020 Dec; 35():120-125. PubMed ID: 32871546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis.
    Wagle NS; Park S; Washburn D; Ohsfeldt R; Kum HC; Singal AG
    Cancer Epidemiol Biomarkers Prev; 2024 Apr; 33(4):463-470. PubMed ID: 38252039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.
    Rich NE; Carr C; Yopp AC; Marrero JA; Singal AG
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e267-e288. PubMed ID: 33387668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma.
    Scaglione S; Adams W; Caines A; Devlin P; Mittal S; Singal AG; Parikh ND
    Dig Dis Sci; 2020 Jun; 65(6):1669-1678. PubMed ID: 31643036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial disparities in clinical presentation, surgical procedures, and hospital outcomes among patients with hepatocellular carcinoma in the United States.
    Chikovsky L; Kutuk T; Rubens M; Balda AN; Appel H; Chuong MD; Kaiser A; Hall MD; Contreras J; Mehta MP; Kotecha R
    Cancer Epidemiol; 2023 Feb; 82():102317. PubMed ID: 36566577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies.
    Ha J; Yan M; Aguilar M; Tana M; Liu B; Frenette CT; Bhuket T; Wong RJ
    J Clin Gastroenterol; 2016; 50(5):423-30. PubMed ID: 26583267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.
    Artinyan A; Mailey B; Sanchez-Luege N; Khalili J; Sun CL; Bhatia S; Wagman LD; Nissen N; Colquhoun SD; Kim J
    Cancer; 2010 Mar; 116(5):1367-77. PubMed ID: 20101732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Racial, ethnic, and socioeconomic disparities impact post-liver transplant survival in patients with hepatocellular carcinoma.
    Huang DC; Yu RL; Alqahtani S; Tamim H; Saberi B; Bonder A
    Ann Hepatol; 2023; 28(5):101127. PubMed ID: 37286167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma.
    Yeo YH; Liang J; Lauzon M; Luu M; Noureddin M; Ayoub W; Kuo A; Sankar K; Gong J; Hendifar A; Osipov A; Friedman ML; Lipshutz HG; Steinberger J; Kosari K; Nissen N; Abou-Alfa GK; Singal AG; Yang JD
    Am J Gastroenterol; 2023 Dec; 118(12):2201-2211. PubMed ID: 37561061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma.
    Yu JC; Neugut AI; Wang S; Jacobson JS; Ferrante L; Khungar V; Lim E; Hershman DL; Brown RS; Siegel AB
    Cancer; 2010 Apr; 116(7):1801-9. PubMed ID: 20143441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
    Ha J; Yan M; Aguilar M; Bhuket T; Tana MM; Liu B; Gish RG; Wong RJ
    Cancer; 2016 Aug; 122(16):2512-23. PubMed ID: 27195481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States.
    Xu L; Kim Y; Spolverato G; Gani F; Pawlik TM
    Hepatobiliary Surg Nutr; 2016 Feb; 5(1):43-52. PubMed ID: 26904556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.
    Stewart SL; Kwong SL; Bowlus CL; Nguyen TT; Maxwell AE; Bastani R; Chak EW; Chen MS
    World J Gastroenterol; 2016 Oct; 22(38):8584-8595. PubMed ID: 27784971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.
    Wang CP; Kuhn J; Shah DP; Schmidt S; Lam YF; MacCarthy D; Tenner L; Ramirez AG
    Cancer Med; 2019 Jun; 8(6):3206-3215. PubMed ID: 30993905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database.
    Gupta A; Omeogu C; Islam JY; Joshi A; Zhang D; Braithwaite D; Karanth SD; Tailor TD; Clarke JM; Akinyemiju T
    Sci Rep; 2023 May; 13(1):8190. PubMed ID: 37210410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in outcomes and access to therapy options in hepatocellular carcinoma.
    Beltrán Ponce S; Gokun Y; Douglass F; Dawson L; Miller E; Thomas CR; Pitter K; Conteh L; Diaz DA
    J Natl Cancer Inst; 2024 Feb; 116(2):264-274. PubMed ID: 37831897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma.
    Wagle NS; Park S; Washburn D; Ohsfeldt RL; Rich NE; Singal AG; Kum HC
    Hepatol Commun; 2022 May; 6(5):1186-1197. PubMed ID: 34796703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.